# Optimal PharmacoTherapy and Invasive Management of Atrial Fibrillation in Patients With Heart Failure

Study · id `cardio:ct-nct07238452` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07238452](<https://clinicaltrials.gov/study/NCT07238452>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07238452

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems; Heart failure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1050 participants.

## Technical summary

Registry record NCT07238452. Randomized; single masking; primary purpose treatment. Start 2026-11-01 (anticipated); primary completion 2032-12-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1050 participants (planned count; ClinicalTrials.gov record NCT07238452, source copy `cardio:ctgov-nct07238452-2026-10-14`, retrieved 2026-10-26)
- Planned start: 2026-11-01 (anticipated) (ClinicalTrials.gov record NCT07238452, source copy `cardio:ctgov-nct07238452-2026-10-14`, retrieved 2026-10-26)
- Primary completion: 2032-12-01 (anticipated) (ClinicalTrials.gov record NCT07238452, source copy `cardio:ctgov-nct07238452-2026-10-14`, retrieved 2026-10-26)
- Completion: 2033-01-01 (anticipated) (ClinicalTrials.gov record NCT07238452, source copy `cardio:ctgov-nct07238452-2026-10-14`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07238452-2026-10-14`, retrieved 2026-10-26)

## The registry's words

- Brief title: Optimal PharmacoTherapy and Invasive Management of Atrial Fibrillation in Patients With Heart Failure
- Acronym: OPTIMal AF-HF
- Condition: Heart Failure With Reduced Ejection Fraction
- Condition: Atrial Fibrillation (AF)
- Intervention (Device): Pulmonary Vein Isolation
- Intervention (Drug): Pharmacological Rate Control
- Lead sponsor: University of British Columbia
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry lists this organization as the lead sponsor: University of British Columbia (`cardio:org-university-of-british-columbia`)

## Provenance

Content hash: b6ebb29e4b0f49bc0506ba679858cf9eeca2cf39ed43be9ee5aa902c06e21660
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
